| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.11.3.629 |
| P698 | PubMed publication ID | 1827591 |
| P2093 | author name string | J Chapman | |
| F Nigon | |||
| D Rouy | |||
| E Anglés-Cano | |||
| P Grailhe | |||
| P433 | issue | 3 | |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 629-638 | |
| P577 | publication date | 1991-05-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu | |
| P478 | volume | 11 |
| Q47272541 | Apolipoprotein(a) size polymorphism in young adults with ischemic stroke |
| Q72548842 | Arterial thrombosis: putative role of lipoprotein(a) |
| Q46953909 | Atherogenesis in transgenic mice expressing human apolipoprotein(a) |
| Q38918257 | Development of lipoprotein(a) siRNAs for mechanism of action studies in non-human primate models of atherosclerosis |
| Q35029916 | Dyslipidaemia in rheumatological autoimmune diseases |
| Q38042396 | Dyslipidemias in the prevention of cardiovascular disease: risks and causality. |
| Q72630916 | Elevated lipoprotein (a) levels in primary nephrotic syndrome |
| Q90235953 | Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties |
| Q35187047 | Farnesoid X receptor represses hepatic human APOA gene expression |
| Q35224510 | Fibrin, Lipoprotein(a), Plasmin Interactions: A Model Linking Thrombosis and Atherogenesisa |
| Q37379082 | Fibrinogen deficiency is compatible with the development of atherosclerosis in mice |
| Q37271062 | Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism |
| Q38297505 | Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). |
| Q37734181 | Levels of Apolipoprotein A1, B100 and Lipoprotein (a) in Controlled and Uncontrolled Diabetic Patients and in Non-Diabetic Healthy People |
| Q30242031 | Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology |
| Q33801207 | Lipoprotein (a), an independent cardiovascular risk marker |
| Q36515765 | Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease |
| Q39002143 | Lipoprotein (a): a historical appraisal |
| Q34078108 | Lipoprotein Lp(a) and atherothrombotic disease. |
| Q62273619 | Lipoprotein(A) in renal transplant recipients |
| Q67903043 | Lipoprotein(a) |
| Q70506625 | Lipoprotein(a) and apolipoproteins B and A-1 in children and coronary vascular events in their grandparents |
| Q24623225 | Lipoprotein(a) as a cardiovascular risk factor: current status |
| Q35195920 | Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes |
| Q77714432 | Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study |
| Q36237559 | Lipoprotein(a): Cellular Effects and Molecular Mechanisms |
| Q35754367 | Lipoprotein(a): biology and clinical importance |
| Q35350215 | Lipoprotein(a): its inheritance and molecular basis of its atherothrombotic role |
| Q37370315 | Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice |
| Q35943015 | Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). |
| Q35905628 | Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction |
| Q41564035 | Pathophysiological implication of the structural domains of lipoprotein(a). |
| Q90261245 | Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis |
| Q38233052 | The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina |
| Q73258244 | The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels |
Search more.